RxDoctor Payments Data
★ My doctorsLook up a doctor →

Kamran Chaudhary, MD

Rheumatology · Schaumburg, ILNPI 1356310338

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 60.8% of it on its own, with 42 other manufacturers making up the rest. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$128,376in general payments, 2019–2025

Across 836 payments — averaging $153.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$78K
  • United Rheumatology$37K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • UCB, Inc.$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $7K from 37 others
$1,275,491in research payments, 2019–2025

Across 283 payments — averaging $4507.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$593K
  • Eli Lilly$171K
  • Sun Pharmaceutical Industries Inc.$170K
  • Amgen$151K
  • E.r. Squibb & Sons, L.L.C.$101K
  • Novartis$54K
  • plus $36K from 3 others

What the payments were for

  • Consulting fees$36,25028%
  • Speaking & faculty fees$71,38856%
  • Travel & lodging$1,9822%
  • Food & beverage$18,59814%
  • Education$1580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)212$78,005
United Rheumatology7$36,532
AbbVie120$1,942
Johnson & Johnson(2 entities)75$1,708
UCB, Inc.65$1,680
Mallinckrodt Hospital Products Inc.53$1,057
AstraZeneca(2 entities)36$955
Lilly USA, LLC34$818
GSK38$811
Octapharma USA, Inc.10$742
E.r. Squibb & Sons, L.L.C.43$742
Novartis34$733
ANI Pharmaceuticals, Inc.15$394
US Oncology Corporate, Inc.4$314
Janssen Scientific Affairs, LLC5$206
Fresenius Kabi USA, LLC7$194
Genentech USA, Inc.10$183
Boehringer Ingelheim9$174
Ultragenyx Pharmaceutical Inc.6$116
Mallinckrodt Enterprises LLC5$107
Tersera Therapeutics LLC4$90
Avanos Medical4$89
Sanofi4$83
Radius Health, Inc.4$76
Organon4$71
Sandoz3$69
Sobi, Inc2$52
Pacira Therapeutics, Inc.2$45
Pfizer2$45
Merck3$44
Kiniksa Pharmaceuticals International, PLC2$42
Bristol Myers Squibb2$39
Genentech, Inc.1$28
Kiniksa Pharmaceuticals, Ltd.1$28
Hospira, Inc.1$26
Aurinia Pharma U.S., Inc.1$20
Biocon Biologics Inc1$19
Oxford Immunotec USA Inc1$19
Pharmacyclics LLC, An Abbvie Company1$18
Teva Pharmaceuticals USA, Inc.1$17
Mylan Institutional Inc.1$17
Cumberland Pharmaceuticals, Inc.1$16
Fidia Pharma USA Inc.2$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,376 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois →

Medicare billing

Part B allowed, 2024
$1,675,512
Medicare patients
192
Services billed
104,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$161,899
Cimzia (2 Pack)Certolizumab Pegol19$132,429
Enbrel SureclickEtanercept14$98,324
RinvoqUpadacitinib11$66,499
BenlystaBelimumab13$61,205
OtezlaApremilast15$43,030
OtrexupMethotrexate/Pf11$8,392
RasuvoMethotrexate/Pf14$7,327
Hydroxychloroquine Sulfate149$4,932
MethotrexateMethotrexate Sodium156$4,098
Allopurinol46$1,653
Azathioprine20$1,620
Colchicine36$1,612
Prednisone175$1,503
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$1,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$1,680$132,42919 claims
AbbVieRinvoq$1,942$66,49911 claims
GSKBenlysta$811$61,20513 claims
AmgenOtezla$78,005$43,03015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Schaumburg

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →